Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine.

Trial Profile

Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Azithromycin (Primary) ; Clofazimine (Primary) ; Ethambutol (Primary) ; Rifampicin
  • Indications Mycobacterium avium complex infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top